熱門資訊> 正文
Innate Pharma报告第一季度业绩
2025-05-13 14:57
- Innate Pharma press release (NASDAQ:IPHA): Q1 revenue amounted to €1.2 million vs €6.6 million for the same period in 2024.
- Revenue from collaboration and licensing agreements mainly resulted from the partial or entire recognition of the proceeds received pursuant to the agreements with AstraZeneca and Sanofi.
- Cash position of €72.5 million as of March 31, 2025, excluding the €15 million received from Sanofi, with a cash horizon to mid-2026.
- Innate Pharma (IPHA) will propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a board of directors structure with a Chief Executive Officer.
- This transformation is part of the company’s strategic plan to simplify and align its governance with international standards.
More on Innate Pharma
- Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript
- Innate Pharma S.A. 2024 Q4 - Results - Earnings Call Presentation
- Innate Pharma: Moving Into The Padcev Space
- Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments
- Seeking Alpha’s Quant Rating on Innate Pharma
推薦文章
港股周報丨三家外賣平臺被約談！「瘋狂星期六」或不再瘋狂；花旗呼籲增持中國互聯網、科技及消費板塊
美股機會日報 | 特朗普放大招！9萬億養老金即將殺入加密市場；美聯儲主席候選人支持7月降息
一周財經日曆 | 特斯拉、谷歌財報重磅來襲！維立志博將於下周五登陸港交所
一圖看懂 | 港股上半年IPO募資額登頂全球！中籤就賺一萬港幣的「大肉籤」你參與了嗎？
黃仁勛年內三度訪華！H20重返中國市場，釋放了什麼信號？
創新葯行情徹底爆發！維立志博-B打新半日孖展超購130倍，凍資近150億港元
新股申購 | 維立志博-B入場費3535.30港元！引入騰訊、易方達等基石投資者
7月財報預告丨迎關税考驗！特斯拉、臺積電放榜在即，美股能否守住漲勢？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
